RIDGEWOOD, N.J., Sept. 21, 2017 -- Atlant Clinical has successfully completed an international, multicenter, randomized, phase IV study in patients with chronic obstructive pulmonary disease (COPD).
The trial was conducted for an international pharma company and included 6,065 patients at 53 sites in 37 cities worldwide. Patient recruitment took nine months and the observation period, twelve months. The trial demonstrated pharmacoeconomic benefits of the investigational product.
The study was the largest one carried out by Atlant Clinical up to date. Several audits performed during the study confirmed trial conduction according to high quality clinical standards.
COPD is caused by a group of progressive respiratory diseases characterized by airway obstruction. According to WHO, there are 65 million people worldwide who suffer moderate to severe COPD. In 2005, more than 3 million people died of COPD, 5% of all deaths globally. According to forecasts, COPD will become the third leading cause of death worldwide by 2030.
Michael Groubman, Chief Executive Officer of Atlant Clinical, said: "We are proud of successfully completing the largest trial in our portfolio and are grateful to our Sponsor for their trust in us. Our extensive experience in pulmonology enabled us to complete the study in strict accordance with the planed timelines while maintaining the highest quality of professional services. The number of enrolled patients demonstrates our strong recruitment capabilities and the wide geographical coverage of our operations. Having close connections with leading principal investigators in Europe and other countries, we are certain of our abilities to complete studies in accordance with agreed timelines.”
About Atlant Clinical
Atlant Clinical is an international CRO, established in 2007, offering a full range of clinical trial and relevant support services throughout the US, Europe, Russia, and Middle East. Atlant Clinical has extensive clinical experience (Phases I–IV) in over 15 therapeutic areas. Atlant Clinical’s team consists of more than 150 experienced employees worldwide. Atlant Clinical has offices in the US, Germany, UK, Russia, Lithuania, and Ukraine. The company’s clients range from some of the world's leading pharmaceutical companies to small and mid-size biotech firms. To learn more about Atlant Clinical, visit www.atlantclinical.com
Contact
To learn more about Atlant Clinical, please contact:
Marietta Sarkisyan, Business Development Manager
76 N. Walnut Street
Ridgewood, NJ 07450
Phone: +1 (201) 616 0037
[email protected]


TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



